Dynavax-- (MARKETWIRE) -- 12/20/11 -- Dynavax Technologies Corporation DVAX announced today the initiation of a proof-of-mechanism clinical trial of the TLR7 and TLR9 inhibitor, DV1179, in systemic lupus erythematosus (SLE) patients. Initiation of this trial entitles Dynavax to receive a $6 million milestone payment from GlaxoSmithKline (GSK) under their worldwide strategic alliance. GSK has an exclusive option to obtain a license to the program following completion of this trial.
Under the agreement, GSK will further develop and commercialize the products. Dynavax stands to receive tiered royalties on sales,
Two years into this trial
What did old Grey pitch to RA Cap, Blackrock, SAC Cap qnd others
is Hep Lisa V just icing ?
Both of these groups had plenty of monies invested prior to November last year.
And what is the Value of a Lupus drug option Worth to GSK ?
And what would Royalties do to Value?
Get out of the BOX*
They recently introduced a new product, a powder solution, 100 percent water soluble, no sugar, no calories.
“You simply put it in your water and you get all the benefit of coffee fruit right away,”
Down the road, plans are to offer Kona Red in other forms — capsules, tablets, nutritional bars, and increased types of beverages.
“You’ll see KonaRed branch out into the nutritional space,”
The days of Dynavax on the cheap are soon to end
As you can see the below list of Smart BUY $ HOLD institutional Investors
have bought before the 2.00 mark
Check the names and do your DD
SAC Capital Advisors' latest 13F report shows that it increased its holdings in , Dynavax Technologies Corporation
132 Institutional Holders
198,810,387 Total Shares Held
FEDERATED INVESTORS INC /PA/ 35,239,308
HEALTHCOR MANAGEMENT, L.P. 20,000,000
RA CAPITAL MANAGEMENT, LLC 17,883,954
WESTFIELD CAPITAL MANAGEMENT 11,535,700
STATE STREET CORP 8,843,407
BROOKSIDE CAPITAL MANAGEMENT 8,000,000
VANGUARD GROUP INC 7,741,236
SAC CAPITAL ADVISORS LP. 7,577,533
BARCLAYS GLOBAL INVESTORS UK 7,387,465
BROADFIN CAPITAL, LLC 7,250,000
POLAR CAPITAL LLP 7,237,882
AMICI CAPITAL, LLC 7,134,100
BLACKROCK FUND ADVISORS 6,424,665
KINGDON CAPITAL MANAGEMENT, 3,814,986
FRANKLIN RESOURCES INC 3,792,500
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition
We estimate that our cash, cash equivalents and marketable securities were approximately $189 million as of December 31, 2013. This amount is preliminary, unaudited, subject to change upon completion of our audit, and may differ from what will be reflected in our audited consolidated financial statements as of and for the year ended December 31, 2013. Additional information and disclosures would be required for a more complete understanding of our financial position and results of operations as of December 31, 2013.
The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed to "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Job Location US-CA-Berkeley
Posted Date 3/4/2014
More information about this job:
This position is responsible for exploratory science to expand the company’s technology platform in oncology immunotherapy. Research activities will be focused towards advancing knowledge and understanding in the field of oncology immunotherapy as well as create the opportunities to publish work to advance the Company’s position is this space.
No Sir the 750 M figure is light likely to be around 1 B by the time we get any approval.
I have put this Question to the board probably 10 time and never got a Bite.
I would think it would double the market share value, But that's why I'm asking I don't know.
O" you see the storm
Low float makes for higher prices when better prospects of Value are brought to light*
Expanding to cover Diabetics would call for a new Blinded test
And Grey will not take any chances not satisfying the FDA third time around.
To evaluate the overall safety of HEPLISAV with respect to clinically significant adverse events; and
To demonstrate the noninferiority of the peak seroprotection rate (SPR) induced by HEPLISAV to Engerix-B in subjects with type 2 diabetes mellitus.
HBV-23 will include 5,500 HEPLISAV subjects and 2,500 Engerix-B subjects, randomized 2:1 and stratified by age and diabetes diagnosis. HEPLISAV subjects will receive two doses at 0 and 1 month, while Engerix-B subjects will receive three doses at 0, 1 and 6 months. All HEPLISAV subjects will be evaluated for safety for one year following the second dose and all potential autoimmune events will be adjudicated by a Safety Evaluation and Adjudication Committee. Immunogenicity assessments will be conducted in a subset of subjects, including those with type 2 diabetes.
"Following extensive discussion with FDA, we've finalized a study design that we believe will provide confidence to the Agency regarding HEPLISAV's safety profile, and importantly, will provide Dynavax with the opportunity to prospectively generate additional immunogenicity data in persons with diabetes, a population for whom there is a clear unmet medical need,"